Identification and functional characterization of EFNA3 as a dual diagnostic biomarker and immune therapeutic target in rectal cancer

Abstract

Background: The Eph/ephrin signaling system has emerged as an important regulator of oncogenic processes, yet its specific involvement in rectal adenocarcinoma (READ) pathogenesis requires further elucidation. This study employed an integrative analytical approach combining computational biology with experimental validation to characterize Eph/ephrin family members in READ, with emphasis on EFNA3.

Methods: We employed an integrative multi-omics approach combining bioinformatics analysis with experimental validation. Transcriptomic data from the Cancer Genome Atlas and Genotype-Tissue Expression were analyzed to evaluate Eph/ephrin family expression, clinical correlations, and immune infiltration patterns. Functional validation was performed using CCK-8, wound healing, transwell migration assays, and Western blotting.

Results: Our integrated multi-omics analysis identified EFNA3 as a dual-function biomarker with both prognostic and immunological relevance in READ. Specifically, EFNA3 expression was elevated in READ tissues and correlated with poor patient prognosis. Functional characterization revealed that EFNA3 contributes to an immunosuppressive tumor microenvironment, marked by reduced cytotoxic lymphocyte infiltration and downregulation of key immune checkpoints. Mechanistically, EFNA3 overexpression promoted rectal cancer cell proliferation and migration, with pathway analysis and Western blot validation implicating Phosphoinositide 3-Kinase (PI3K)/Ak strain Transforming (AKT)/Mechanistic Target of Rapamycin (mTOR) signaling activation. Furthermore, EFNA3 expression exhibited significant correlations with drug sensitivity and potential associations with traditional Chinese herbs, suggesting its broader implications in therapeutic response and alternative medicine approaches.

Conclusion: Our findings establish EFNA3 as a key regulator of READ progression, driving both tumor aggressiveness and immune evasion. These results provide a translational framework for targeting EFNA3-mediated pathways, suggesting combined PI3K/AKT/mTOR inhibition and immune modulation as a potential therapeutic strategy for aggressive READ.

Keywords

bioinformatics / EFNA3 / Eph/ephrin / immunotherapy / prognosis / rectal cancer

References

[1] Bray F , Laversanne M , Sung H , et al. Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74 (3): 229- 263.

[2] Siegel RL , Miller KD , Fedewa SA , et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017; 67 (3): 177- 193.

[3] Germani MM , Carullo M , Boccaccino A , Conca V , Masi G . The evolving landscape of immunotherapy in locally advanced rectal cancer patients. Cancers (Basel). 2022; 14 (18): 4453.

[4] Nikolouzakis TK , Chrysos E , Docea AO , et al. Current and future trends of colorectal cancer treatment:exploring advances in immunotherapy. Cancers (Basel). 2024; 16 (11): 1995.

[5] Dai Y , Zhao W , Yue L , et al. Perspectives on immunotherapy of metastatic colorectal cancer. Front Oncol. 2021; 11: 659964.

[6] Zhao P , Li L , Jiang X , Li Q . Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. J Hematol Oncol. 2019; 12 (1): 54.

[7] Eph Nomenclature Committee . Unified nomenclature for Eph family receptors and their ligands, the ephrins. Cell. 1997; 90 (3): 403- 404.

[8] Shin WS , Park MK , Lee YH , Kim KW , Lee H , Lee ST . The catalytically defective receptor protein tyrosine kinase EphA10 promotes tumorigenesis in pancreatic cancer cells. Cancer Sci. 2020; 111 (9): 3292- 3302.

[9] Guo X , Yang Y , Tang J , Xiang J . Ephs in cancer progression: complexity and context-dependent nature in signaling, angiogenesis and immunity. Cell Commun Signal. 2024; 22 (1): 299.

[10] Du J , Du Y , Chen L , Liu H . IL-17 promotes melanoma through TRAF2 as a scaffold protein recruiting PIAS2 and ELAVL1 to induce EPHA5. Biochim Biophys Acta Mol Cell Res. 2023; 1870 (7): 119547.

[11] Chen Y , Zhang H , Zhang Y . Targeting receptor tyrosine kinase EphB4 in cancer therapy. Semin Cancer Biol. 2019; 56: 37- 46.

[12] Mezquita B , Reyes-Farias M , Pons M . FDA-approved antivirals ledipasvir and daclatasvir downregulate the Src-EPHA2-Akt oncogenic pathway in colorectal and triple-negative breast cancer cells. Biomed Pharmacother. 2024; 179: 117325.

[13] Li GX , Ma B , Zhang S , et al. EphB4-ephrin-B2 are targets in castration resistant prostate cancer. Br J Cancer. 2025; 132 (8): 679- 689.

[14] Scarini JF , Goncalves MWA , de Lima-Souza RA , et al. Potential role of the Eph/ephrin system in colorectal cancer:emerging druggable molecular targets. Front Oncol. 2024; 14: 1275330.

[15] Talia M , Cirillo F , Spinelli A , et al. The Ephrin tyrosine kinase a3 (EphA3) is a novel mediator of RAGE-prompted motility of breast cancer cells. J Exp Clin Cancer Res. 2023; 42 (1): 164.

[16] Darling TK , Lamb TJ . Emerging roles for Eph receptors and ephrin ligands in immunity. Front Immunol. 2019; 10: 1473.

[17] Fukuda R , Beppu S , Hinata D , Kamada Y , Okiyoneda T . Perturbation of EPHA2 and EFNA1 trans binding amplifies inflammatory response in airway epithelial cells. iScience. 2025; 28 (2): 111872.

[18] Liu T , Zhao M , Peng L , et al. WFDC3 inhibits tumor metastasis by promoting the ERbeta-mediated transcriptional repression of TGFBR1 in colorectal cancer. Cell Death Dis. 2023; 14 (7): 425.

[19] Mi J , Zhang W , Ren Y , et al. Neuronal guanine nucleotide exchange factor promotes the axonal growth and cancer cell proliferation via Ephrin-A3/EphA2 axis in lung adenocarcinoma. J Transl Med. 2025; 23 (1): 246.

[20] Wang G , Xu G , Fan Y , et al. EPHA5 promotes cell proliferation and inhibits apoptosis in Follicular Thyroid Cancer via the STAT3 signaling pathway. Oncogenesis. 2025; 14 (1): 12.

[21] Huang S , Dong C , Zhang J , Fu S , Lv Y , Wu J . A comprehensive prognostic and immunological analysis of ephrin family genes in hepatocellular carcinoma. Front Mol Biosci. 2022; 9: 943384.

[22] Liu J , Yuan Q , Chen X , et al. Prognostic and therapeutic value of the Eph/Ephrin signaling pathway in pancreatic cancer explored based on bioinformatics. Sci Rep. 2024; 14 (1): 17650.

[23] Xie R , Yuan M , Jiang Y . The pan-cancer crosstalk between the EFNA family and tumor microenvironment for prognosis and immunotherapy of gastric cancer. Front Cell Dev Biol. 2022; 10: 790947.

[24] Giannopoulos K , Karikis I , Byrd C , et al. Eph/ephrin-mediated immune modulation:a potential therapeutic target. Front Immunol. 2025; 16: 1539567.

[25] Li YC , Zhang L , Wang YT , et al. Role of EFNAs in shaping the tumor immune microenvironment and their impact on pancreatic adenocarcinoma prognosis. Cancer Manag Res. 2025; 17: 693- 712.

[26] Xu S , Zheng Y , Ye M , et al. Comprehensive pan-cancer analysis reveals EPHB2 is a novel predictive biomarker for prognosis and immunotherapy response. BMC Cancer. 2024; 24 (1): 1064.

[27] Lertsumitkul L , Iliopoulos M , Wang SS , et al. EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses. J Immunother Cancer. 2024; 12 (8): e009486.

[28] Deng M , Tong R , Zhang Z , et al. EFNA3 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with lung adenocarcinoma. Cancer Cell Int. 2021; 21 (1): 535.

[29] Ganesh K , Stadler ZK , Cercek A , et al. Immunotherapy in colorectal cancer:rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019; 16 (6): 361- 375.

[30] Williams CJM , Peddle AM , Kasi PM , et al. Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers:therapeutic strategies and putative biomarkers of response. Nat Rev Clin Oncol. 2024; 21 (12): 839- 851.

[31] Yin L , Yang F , Wang W , et al. PSMA-targeted nanoparticles with PI3K/mTOR dual inhibitor downregulate P-glycoprotein and inactivate myeloid-derived suppressor cells for enhanced chemotherapy and immunotherapy in prostate cancer. Adv Mater. 2025; 37 (26): e2415322.

RIGHTS & PERMISSIONS

The Author(s). Advanced Chinese Medicine published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.